<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Using a multiparameter flow cytometry assay enumerating cells positive for CD13, CD14 and CD66 antigens, we determined the asynchronous CD14/CD66 co-expression in unselected bone marrow and peripheral blood samples with suspected malignant <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">blood disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>CD14/CD66 co-expression &gt; or = 5% were found in 131/691 bone marrow samples </plain></SENT>
<SENT sid="2" pm="."><plain>Only 55 of these exhibited an identifiable population in 2-parameter flow cytometry histograms </plain></SENT>
<SENT sid="3" pm="."><plain>Of the 55 samples 43 (78%) came from patients with myeloid disorders; e.g. 11 with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, 15 with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> and 17 with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Only one of these 17 cases was a de novo case, while 8 were secondary to another malignant haematological disease and 8 were from the period after cytoreductive therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Notably, CD14/CD66 co-expression patterns were related to disease categories; e.g. in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> following a dysplastic phase the co-expression displayed two subsets in peripheral blood, low-avidity CD14 and low-avidity CD66, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The latter disease category also exhibited these 2 subsets in bone marrow </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> other cases, the CD14/CD66 co-expression in bone marrow was <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, abnormal CD14/CD66 co-expression might be a valuable parameter in defining asynchronous myelopoiesis in malignant myeloid disorders, especially <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> and secondary <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo> </plain></SENT>
</text></document>